Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
Key Takeaways
Before diving into the details, keep these core points in mind as you evaluate GLP-1 care in Florida.
- Florida’s GLP-1 market is crowded with unqualified providers and substandard compounded products, so patients must verify true medical-grade, physician-led care.
- Medical-grade GLP-1 means FDA-approved or properly compounded medications from licensed 503A/503B pharmacies, prescribed and monitored by a board-certified physician with baseline labs and ongoing supervision.
- Patients should confirm the prescribing physician’s board certification, Florida licensure, and that the medication comes with batch-specific Certificates of Analysis from a verified compounding pharmacy.
- Red flags include no in-person or thorough medical evaluation, unverifiable pharmacies, suspiciously low prices, and guarantees of dramatic results that violate FDA advertising rules.
- For physician-led GLP-1 care in Florida, schedule your consultation at Mirror Plastic Surgery to receive personalized protocols with rigorous safety standards.
What Medical-Grade GLP-1 Means In Everyday Care
Medical-grade GLP-1 refers to FDA-approved medications such as semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro), or compounded versions produced by licensed 503A or 503B pharmacies under strict quality standards, always prescribed and monitored by a licensed physician. This standard rests on three pillars: product quality and sourcing, physician supervision, and personalized dosing with ongoing monitoring.
The distinction between FDA-approved drugs and compounded peptides is critical. Compounded GLP-1 drugs are not FDA-approved and have not been reviewed by the agency for safety, effectiveness, or quality prior to marketing. Compounded medications differ from generics, because generic drugs undergo FDA premarket approval and are determined to be therapeutically equivalent to their brand-name counterparts, while compounded drugs do not.
The legal landscape for compounding has also shifted significantly. The FDA removed semaglutide from its shortage list in February 2025 and tirzepatide in October 2024, ending the primary legal basis for large-scale 503B compounding. Many Florida patients and some clinics have not fully absorbed this change. Providers that continue to dispense mass-compounded GLP-1s without documented patient-specific clinical necessity are operating outside current regulatory guidance.
Medical-grade care also requires a proper clinical evaluation, appropriate baseline lab work, and structured ongoing supervision. A brief questionnaire alone does not qualify as adequate medical oversight. With this definition in mind, the next step is confirming that any provider you consider actually meets these standards.
How To Verify A Provider’s Credentials: The Florida Checklist
Before choosing any GLP-1 provider in Florida, walk through these five essentials to confirm medical-grade care.
- Board Certification And Licensure: Confirm the prescribing physician is board-certified, for example by the American Board of Plastic Surgery or the American Board of Obesity Medicine, and holds an active, unrestricted Florida medical license. You can verify both credentials through the Florida Department of Health MQA portal, and cross-check the provider’s NPI number through the NPPES NPI Registry (npiregistry.cms.hhs.gov).
- Physician-Led Medical Supervision: In Florida, the exam before prescribing a GLP-1 must be performed by a physician, an APRN, or a physician assistant, and cannot be delegated to a registered nurse, LPN, or medical assistant. A physician should oversee your initial evaluation and remain involved in your ongoing care.
- Pharmacy Sourcing: Ask which pharmacy compounds or dispenses the medication, then verify that it is a licensed 503A pharmacy or FDA-registered 503B outsourcing facility. Request a Certificate of Analysis confirming identity, purity, sterility, and endotoxin testing. A legitimate Certificate of Analysis should include identity confirmation via HPLC or mass spectrometry, purity percentage, endotoxin testing via the LAL method, sterility test results, a lot number matching the vial, and the issuing lab’s ISO/IEC 17025 accreditation.
- Batch Testing And Quality Control: Reputable providers source from pharmacies that conduct third-party potency and sterility testing on every batch. Inability to name the pharmacy or provide documentation signals a serious quality concern.
- Personalized Treatment Plans: Your protocol should reflect your labs, medical history, and goals. Florida Administrative Code 64B8-9.012 requires providers to document BMI of 30 or higher (or 27 or higher with comorbidities), obtain written informed consent, and re-evaluate patients at least every three months. Legitimate providers also require baseline blood work, including CBC, CMP, HbA1c, and a thyroid panel, before starting therapy.
Once you understand how to verify credentials, it becomes easier to see how Florida law and federal enforcement shape safe GLP-1 care.
Florida’s Legal And Regulatory Landscape For GLP-1 Providers
Florida Statute 456.47 permits telehealth prescribing by Florida-licensed physicians, which makes remote GLP-1 care accessible across the state. Out-of-state providers must register with the Florida Department of Health before treating Florida patients, and Florida law holds telehealth providers to the exact same standard of care as in-person services, with no reduction in clinical expectations.
Florida Administrative Code 64B8-9.012 requires providers to document BMI thresholds, conduct follow-up re-evaluations at least every three months, and provide each patient with Florida’s Weight-Loss Consumer Bill of Rights. These rules apply whether care occurs in person or via telehealth.
FDA enforcement has escalated substantially in 2026. In June 2026, the FDA issued 25 warning letters to telehealth companies for marketing false and misleading claims about compounded versions of tirzepatide and semaglutide, following an earlier series of 30 warning letters sent in March 2026. Florida has already seen direct impact: GenoGenix, a Boca Raton compounding pharmacy, received an FDA warning letter in January 2026 citing insanitary manufacturing conditions, subpotent drugs, and inadequate contamination-prevention systems, and initiated a voluntary recall of semaglutide and tirzepatide products in July 2025 due to sterility problems.
Additionally, Florida’s SB 1842, signed into law in March 2026, requires patients receiving compounded GLP-1 analogs through telehealth to have at least one in-person evaluation annually with a Florida-licensed physician, with enforcement beginning July 1, 2026. With this legal context in place, you can more easily recognize red flags when a provider falls short.
Red Flags: How To Spot An Unsafe GLP-1 Provider
Florida’s saturated GLP-1 market includes providers that prioritize volume over clinical rigor, so clear warning signs help you protect yourself.
- No Medical Evaluation: The good-faith examination is the single most enforced documentation requirement in GLP-1 compliance, and the absence of a pre-treatment lab panel is the most common chart deficiency cited in 2024–2026 board reviews. Providers who prescribe based only on a brief online questionnaire are operating outside the standard of care.
- “Research Peptides” Sold Online: Grey-market GLP-1 products marketed as “research peptides,” powders, self-mixing kits, or other products not reviewed by the FDA are not legitimately compounded medications and may be unsafe.
- No Named Physician: Clinics that cannot identify the board-certified physician overseeing your care present a disqualifying red flag.
- Unverifiable Pharmacy: Providers who cannot name their compounding pharmacy or supply batch-specific Certificates of Analysis are cutting corners on quality.
- Suspiciously Low Prices: Clinics advertising GLP-1 treatment at dramatically discounted rates may be cutting corners on compounding sources, underdosing, or lacking medical oversight.
- Guaranteed Results: Claims like “guaranteed to lose 30 pounds in 30 days” or “no side effects” are violations of FDA regulations on drug advertising.
If you notice any of these warning signs, move on to a safer option. For providers who appear legitimate, the next step is asking targeted questions during your consultation.
If you are ready to work with a provider who meets every item on this checklist, schedule a GLP-1 consultation with Mirror Plastic Surgery and start with physician-led, transparent care.
Questions To Ask Before Starting GLP-1 Therapy
Use this checklist during your initial consultation to confirm that you will receive medical-grade GLP-1 care.
- Are you a board-certified physician, and will you personally oversee my treatment?
- Do you require lab work before starting, and which panels do you order?
- Which pharmacy do you use, and are they 503A or 503B certified?
- Can you provide a Certificate of Analysis for the medication I will receive?
- How often will I have follow-up appointments, and who monitors my progress?
- What is your protocol for managing side effects or complications?
- What happens if I need to stop treatment, and do you offer a maintenance or step-down plan?
Once you know what to ask, you can better compare providers and understand what sets high-level practices apart.
Why Mirror Plastic Surgery Sets The Standard In Florida
Mirror Plastic Surgery offers physician-led GLP-1 care that goes beyond the typical medical spa or telemedicine clinic. Florida has many GLP-1 options, yet few deliver true concierge-level care anchored in rigorous clinical standards.
Dr. Akash is a Harvard-educated, Johns Hopkins-trained, board-certified plastic surgeon who brings deep expertise in physiology and metabolic health to every peptide protocol. His background, including neuroscience training at MIT, medical innovation training through the Stanford University Biodesign Innovation Fellowship, and fellowship training in aesthetic surgery at the Manhattan Eye Ear & Throat Hospital, positions him uniquely to evaluate both the clinical science and the individual patient behind every GLP-1 protocol.
Every Mirror patient receives a comprehensive 30–60 minute consultation, in-depth lab analysis, and a personalized peptide protocol. This protocol is designed around each patient’s unique physiology and goals, rather than a one-size-fits-all program. Mirror sources peptides exclusively from reputable providers with rigorous batch testing, which supports product quality, purity, and accurate dosing.
Patients receive direct, 24/7 access to Dr. Akash via text for ongoing support, questions, and refill requests. Services are available in person in St. Petersburg/Tampa and remotely across Florida, with full physician oversight throughout.
Start your personalized GLP-1 protocol with Dr. Akash Chandawarkar by booking a consultation at Mirror Plastic Surgery.
Frequently Asked Questions
Are GLP-1 Peptides FDA-Approved?
FDA-approved GLP-1 medications include semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), as well as liraglutide (Saxenda) and the newer oral option orforglipron (Foundayo). As noted earlier, compounded versions are not FDA-approved and have not undergone the same premarket review for safety, effectiveness, or quality. The main risk in GLP-1 therapy comes from obtaining medications from unregulated or substandard sources without proper medical supervision. GLP-1 medications have been used to treat diabetes for over 20 years, and semaglutide specifically has been available since approximately 2017. At Mirror Plastic Surgery, every protocol is sourced from reputable compounding pharmacies with batch testing and overseen by a board-certified physician.
What Is The Difference Between Semaglutide And Tirzepatide?
Both medications are GLP-1 receptor agonists used for weight management and metabolic health. Tirzepatide also targets GIP (glucose-dependent insulinotropic polypeptide) receptors, which gives it a dual mechanism of action. In the SURMOUNT-5 head-to-head trial, the first randomized clinical trial to compare the two drug classes directly, tirzepatide produced approximately 20.2% mean body-weight loss versus 13.7% for semaglutide over comparable periods.1
The STEP 1 trial showed that semaglutide 2.4 mg weekly produced approximately 14.9% mean body-weight reduction over 68 weeks versus 2.4% with placebo.1 The choice between these medications depends on your individual physiology, medical history, and goals. A physician who has reviewed your labs can guide that decision.
Can I Get GLP-1 Therapy Via Telehealth In Florida?
Yes. Florida Statute 456.47 permits telehealth prescribing by Florida-licensed physicians, and GLP-1 medications like semaglutide and tirzepatide are not controlled substances, so clinicians can prescribe them via telehealth without DEA restrictions. Florida holds telehealth providers to the same standard of care as in-person providers, so a static online questionnaire rubber-stamped by a clinician does not constitute a valid exam.
As mentioned in the legal landscape section, SB 1842 requires an annual in-person evaluation for telehealth patients receiving compounded GLP-1 analogs. Mirror Plastic Surgery offers both in-person consultations in St. Petersburg/Tampa and remote care across Florida, with full physician oversight throughout.
What Are The Common Side Effects Of GLP-1 Medications?
Common side effects include nausea, vomiting, diarrhea, and loss of appetite, particularly when starting the medication or increasing the dose. Other side effects can include dizziness, mild tachycardia, headaches, and temporary injection-site reactions. Rare but serious risks include pancreatitis, medullary thyroid cancer, and acute kidney injury.
GLP-1 medications carry a boxed warning for thyroid C-cell tumors, and patients with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome should avoid them. Medical supervision is essential for screening contraindications before starting and for managing any side effects that arise during treatment. Mirror Plastic Surgery conducts a full contraindication review and baseline lab panel before initiating any GLP-1 protocol.
What Happens If I Stop Taking GLP-1 Medication?
Research indicates that patients regain approximately two-thirds of lost weight within a year of stopping GLP-1 medication and returning to standard care.1 This pattern reflects the chronic nature of metabolic and weight management conditions. Similar to stopping blood pressure medication, the underlying condition usually persists after treatment ends.
A supervised maintenance protocol or gradual taper, planned in advance with your physician, is essential for sustaining results. Mirror Plastic Surgery builds long-term maintenance planning into every GLP-1 protocol from the outset and treats weight management as an ongoing medical condition rather than a short-term program.
This article is for educational purposes and does not replace medical advice. Peptides are not FDA-approved for all uses; consult a qualified physician before beginning any peptide therapy.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
